Clinical Trials Search

Our researchers are currently in need of adult and pediatric study participants to help us pursue better treatments and cures. Participants may receive medical evaluations and procedures, study medication, disease-related education and possible financial compensation for time, travel and participation.

 

Select a Condition or Specialty



The PROMISE Study: An Observational Study of Triple Combination Therapy for Cystic Fibrosis

This is an observational study to evaluate the biological and clinical effects of triple-combination therapy (TCT), elexacaftor/tezacaftor/ivacaftor, in people with cystic fibrosis (CF) before and after starting this therapy, as prescribed by their doctor.

  • Gender: Any Gender
  • Ages: 12+
  • Compensation: Provided
  • Time Required: 6 visits over 25 months

Triple Combination CF Medication for Less Common Genetic Mutations

Researchers want to investigate lung and digestive functions in CF patients with an investigational triple combination therapy.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 6 visits approximately every 2 weeks during the 12 week trial.

MANDALA Asthma Study

New study drug combines two medications known for asthma relief may help manage the symptoms of moderate to severe asthma in both children and adults.

  • Gender: Any Gender
  • Ages: 4+
  • Compensation: Provided
  • Time Required: After screening, treatment will last from 24 to 36 weeks

Understanding the Genetics of Asthma

Doctors today are still learning about the causes of asthma. With just an hour of your time, you can help our researchers look deeper into the genetics of the disease and develop better treatment options

  • Gender: Any Gender
  • Ages: 18-75
  • Compensation: Provided
  • Time Required: 1-2 office visits totaling up to 1.5 hours

Cystic Fibrosis Medication for Gating Mutations

This study is evaluating the safety and effectiveness of a new investigational medication called VX-561, an altered form of KALYDECO® (generic: ivacaftor), compared to the original ivacaftor.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 8 visits up to 20 weeks

Atopic Dermatitis & Skin Infections

National Jewish Health researchers are trying to determine why people with atopic dermatitis or eczema are more susceptible to bacterial infections. Learn how you can participate in our research study.

  • Gender: Any Gender
  • Ages: 18-65
  • Compensation: Provided
  • Time Required: Up to 3 visits or approximately 3 hours

Treating Insomnia & OSA with Cognitive Behavioral Therapy

Does your mind race at night when you're trying to sleep? Our researchers are studying how people with insomnia and obstructive sleep apnea can benefit from cognitive behavioral therapy, a goal-oriented type of treatment that aims to identify and change inaccurate or negative thinking patterns...

  • Gender: Any Gender
  • Ages: 21-80
  • Compensation: Provided
  • Time Required: Not Specified

Identifying Characteristics and Patterns of Asthma

Our researchers are working to identify the clinical, physiologic, genetic and molecular characteristics of asthmatics.

  • Gender: Any Gender
  • Ages: 5+
  • Compensation: Provided
  • Time Required: 2-4 office visits and up to 3 follow up phone calls

Impact of triple Combination Therapy for People with CF with Sinusitis

In addition to its impact on lung function and sweat chloride, a new medication regimen may improve chronic sinusitis signs and symptoms and sense of smell for people with CF.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 6 months

New Trial Medication for Pulmonary Arterial Hypertension

By adding a new investigational Pulmonary Arterial Hypertension (PAH) medication to your current therapy, you could experience relaxed and widened artery walls.

  • Gender: Any Gender
  • Ages: 18-75
  • Compensation: Provided
  • Time Required: Up to 42 months

Investigational PAH Medication CXA-10

A new investigational medication for Pulmonary Arterial Hypertension is thought to treat inflammation and lower the pressure in blood vessels from the heart to lungs.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: Up to 134 days

The Immunoregulatory Role of Alveolar Macrophages in Chronic Beryllium Disease

By participating in our study, you can help forward research on lung disease. Our researchers are hoping to learn more about the blood cells involved in the development of scarring lung diseases and create new treatment therapies.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 5 hours over 2 visits

New Medication for Early-Stage Non-small cell Lung Cancer

Already approved for advanced non-small cell lung cancer, atezolizumab is a drug that may help those with early-stage lung cancer, as well. Participants in this clinical trial may take atezolizumab in conjunction with their chemotherapy treatments.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Not Provided
  • Time Required: The screening period may last up to 6 weeks and involve up to 2 visits to the clinic.

Hypersensitivity Pneumonitis and the Immune System

Help us look at how specific white blood cells are associated with hypersensitivity pneumonitis (HP) and impact how your disease affects you.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: Approximately 9 hours over 3 study visits

New Investigational Drug for CF Patients with NTM Infection

A new study is looking at an investigational drug that stimulates immune response to fight infection. If you have cystic fibrosis and an ongoing mycobacterial infection, this trial may be right for you.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: Study involvement will last for about 18 months.

New Medication for Osteoarthritis Knee Pain

Do you have mild to moderate osteoarthritis in your knee? Our researchers are conducting a study on an FDA-approved drug that may reduce osteoarthritis knee pain and improve function.

  • Gender: Any Gender
  • Ages: 21-80
  • Compensation: Provided
  • Time Required: 5 visits over 12 months

Lung Injury from Military Deployment

The purpose of this study is to learn more about lung disease found in contractors and U.S. military personnel serving in Iraq and Afghanistan after September 11, 2001.

  • Gender: Any Gender
  • Ages: 18-70
  • Compensation: Provided
  • Time Required: 1 to 2 visits

Pulmonary Sarcoidosis Investigational Medication

This research study evaluates an investigational medication called Acthar® Gel (Acthar) as a potential treatment of pulmonary sarcoidosis.

  • Gender: Any Gender
  • Ages: 18-90
  • Compensation: Provided
  • Time Required: Participants in the study inject the medication twice a week at home and have appointments every 4 weeks.

Eczema & Inflammation

National Jewish Health researchers are studying a new phosphate cream that could reduce painful inflammation. Children ages 2 to 17 with atopic dermatitis may qualify. Learn more.

  • Gender: Any Gender
  • Ages: 2-17
  • Compensation: Provided
  • Time Required: 5 visits over 12 weeks

Sexual and Reproductive Health Survey of Women with Cystic Fibrosis

The purpose of this research study is to identify the general and disease-specific sexual and reproductive health concerns of women with Cystic Fibrosis (CF).

  • Gender: Any Gender
  • Ages: 25+
  • Compensation: Provided
  • Time Required: 25-40 minutes to complete one online survey

Link Between Rheumatoid Arthritis & Lung Disease

Our researchers are trying to understand the connection, as well as how to prevent and treat lung disease in RA patients.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Not Provided
  • Time Required: 6 in-person visits, performed every year over 4 years

ILD & Early Rheumatoid Arthritis

Our researchers are trying to understand how interstitial lung disease (ILD) develops in people with rheumatoid arthritis (RA), and how it may impact their quality of life.

  • Gender: Any Gender
  • Ages: 18-90
  • Compensation: Not Provided
  • Time Required: 5 in-person visits over 18 months

PAH & Scleroderma Medication Study

New drug, Tecfidera, may help with pulmonary arterial hypertension (PAH) by reducing inflammation.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 6 visits over 40 weeks

Idiopathic Pulmonary Fibrosis (IPF)

The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).

  • Gender: Any Gender
  • Ages: 40-95
  • Compensation: Provided
  • Time Required: 5 visits over a 6-month period, visits are every 3 months

Current & Former Smokers Needed for Lung Research Study

Our researchers are studying the lungs of current and former smokers to understand how to improve the diagnosis and treatment of Chronic Obstructive Pulmonary Disease (COPD), a disease that is common among smokers. You do not need to have COPD to participate in this study.

  • Gender: Any Gender
  • Ages: 55-77
  • Compensation: Provided
  • Time Required: 1-2 hour visit (can be scheduled immediately after your CT if there is space available)

Immune Pathways & Development of Sarcoidosis

If you are an adult with sarcoidosis who is not on immunosuppressive therapy, you may be able to help our researchers learn more about different types of sarcoidosis and how it develops.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: Up to 2 visits

Mineral Dust & Lung Disease

Our researchers are studying lung diseases that develop from inhaling mineral dust over time. Although the cause of diseases such as "black lung" are known, it is not well understood why some people develop these diseases and others don't.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Not Provided
  • Time Required: Not Specified

Impact of Combination Therapy on Cystic Fibrosis (TEACH Study)

The purpose of this study is to determine how two medications, azithromycin and inhaled tobramycin, work when taken together to treat cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) lung infections.

  • Gender: Any Gender
  • Ages: 12+
  • Compensation: Provided
  • Time Required: 3 visits over 6 weeks totaling up to 7 hours

New Medication for Uncontrolled Eczema

Are you one of the many people with atopic dermatitis (eczema) who continues to have dry, itchy skin, and repeat infections that are not controlled by your medicine? Our researchers are seeking participants for a clinical trial that will test a medication called dupilumab that was recently...

  • Gender: Any Gender
  • Ages: 18-75
  • Compensation: Provided
  • Time Required: 10 visits and 1 telephone call over about 6-7 months

Combination Therapy for Pediatric Asthma Patients

Our researchers are studying an investigational combination of medications, one used to treat asthma in adults and the other not yet approved to treat adult asthma, to determine if it can improve symptoms and lung function in asthma patients age 5 to 17.

  • Gender: Any Gender
  • Ages: 5-17
  • Compensation: Provided
  • Time Required: 7 visits up to 29 weeks

Teens Age 12-17 with Asthma

Our researchers are studying an investigational medication to determine if it improves lung function in teens with asthma. By blocking a key receptor that causes inflammation in the lungs, the medication may improve and prevent symptoms such as wheezing and shortness of breath.

  • Gender: Any Gender
  • Ages: 12-17
  • Compensation: Provided
  • Time Required: About 9 visits over approximately 19 weeks

New Antibody Targets Severe Asthma

Is your asthma poorly controlled despite using inhalers? Our researchers are studying an investigational medicine that targets a substance known to play a role in causing asthma. You may be able to help them determine if this medication is effective in treating severe asthma.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 19 visits over 69-71 weeks

Investigational Drug Targets Cystic Fibrosis Mutation and Regulator

Our researchers are studying glycerol phenylbutyrate (GPBA), also known as RAVICTI®, to determine how safe it is and how well people tolerate it in the treatment of cystic fibrosis (CF).

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 5 visits totalling up to 21 hours

Rheumatoid Arthritis & Interstitial Lung Disease Medication

Do you have rheumatoid arthritis and interstitial lung disease (RA-ILD)? You may be able to help our researchers determine if people with RA-ILD can benefit from a medication called Pirfenidone, which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic...

  • Gender: Any Gender
  • Ages: 18-85
  • Compensation: Provided
  • Time Required: 10 visits & 1 phone call (22 hours over 56 weeks)

Link Between Eczema & Food Allergies in Newborns

Are you pregnant? Do you have a family history of allergic disease (asthma, eczema, environmental allergies, hay fever, etc.)? You may be able to help our researchers determine if your child and others are at risk of developing eczema and food allergies.

  • Gender: Any Gender
  • Ages: Parents 18-50, newborns 3-6 months
  • Compensation: Not Provided
  • Time Required: Four 1-hour visits over 6 months

Healthy Participants Needed for Lung Disease Study

Are you 18 or older with no history of chronic lung conditions? You may be able to help our researchers better understand lung disease. Compensation provided.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 60-90 minute session

OPUS Registry for Patients Using Opsumit®

The purpose of this study is to learn more about how Opsumit® (the commercial form of the medication macitentan) is used in clinical practice to treat pulmonary arterial hypertension (PAH) and other conditions.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 1 year

Investigational Medication for COPD Lung Damage

Adults age 40 or older are needed to help our researchers determine if an investigational medication can help slow damage to the lungs in people who have COPD with emphysema.

  • Gender: Any Gender
  • Ages: 40+
  • Compensation: Provided
  • Time Required: 7 visits, approximately 19 hours

Investigational Medication Sirolimus for Lymphangioleiomyomatosis (LAM)

The purpose of this study is to see if a drug called sirolimus slows development of lymphangioleiomyomatosis (LAM), a lung disease in which abnormal cells growing inside the lungs prevent them from working properly.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 2 years

Early-Stage Lung Cancer Surgery vs. Radiation Therapy Comparison

The purpose of this study is to gather information about treatment of early-stage lung cancer in order to compare the effectiveness of surgery versus radiation therapy, potentially improving outcomes for patients with early-stage lung cancer.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 4 hours, 45 mins.

Can Investigational Drug Benefit Lung Cancer Surgery Patients?

The purpose of this clinical trial is to see if it better to receive an investigational medication or no further treatment after surgery (and possibly chemotherapy) to remove non-small cell lung cancer (NSCLC).

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Not Provided
  • Time Required: Up to 12 months

Can Investigational Medication Benefit FHP Patients?

The purpose of this clinical trial is to study the safety and potential benefits of treating fibrotic hypersensitivity pneumonitis (FHP) with an investigational medication.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 8 visits and 6 phone calls totaling about 12 hours of participation over 13 months

Atopic Dermatitis (Eczema) & Skin-Infection Risk

If you or your child age 3 or older has atopic dermatitis (eczema), you may be able to help our researchers learn why some people with eczema have increased risk of skin infection.

  • Gender: Any Gender
  • Ages: 3-80
  • Compensation: Provided
  • Time Required: 1 or more visits

Pulmonary Fibrosis & Genetic Factors

The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.

  • Gender: Any Gender
  • Ages: Not Specified
  • Compensation: Not Provided
  • Time Required: Not Specified

The PROMISE Study: An Observational Study of Triple Combination Therapy for Cystic Fibrosis

This is an observational study to evaluate the biological and clinical effects of triple-combination therapy (TCT), elexacaftor/tezacaftor/ivacaftor, in people with cystic fibrosis (CF) before and after starting this therapy, as prescribed by their doctor.

  • Gender: Any Gender
  • Ages: 12+
  • Compensation: Provided
  • Time Required: 6 visits over 25 months

Triple Combination CF Medication for Less Common Genetic Mutations

Researchers want to investigate lung and digestive functions in CF patients with an investigational triple combination therapy.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 6 visits approximately every 2 weeks during the 12 week trial.

MANDALA Asthma Study

New study drug combines two medications known for asthma relief may help manage the symptoms of moderate to severe asthma in both children and adults.

  • Gender: Any Gender
  • Ages: 4+
  • Compensation: Provided
  • Time Required: After screening, treatment will last from 24 to 36 weeks

Understanding the Genetics of Asthma

Doctors today are still learning about the causes of asthma. With just an hour of your time, you can help our researchers look deeper into the genetics of the disease and develop better treatment options

  • Gender: Any Gender
  • Ages: 18-75
  • Compensation: Provided
  • Time Required: 1-2 office visits totaling up to 1.5 hours

Cystic Fibrosis Medication for Gating Mutations

This study is evaluating the safety and effectiveness of a new investigational medication called VX-561, an altered form of KALYDECO® (generic: ivacaftor), compared to the original ivacaftor.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 8 visits up to 20 weeks

Atopic Dermatitis & Skin Infections

National Jewish Health researchers are trying to determine why people with atopic dermatitis or eczema are more susceptible to bacterial infections. Learn how you can participate in our research study.

  • Gender: Any Gender
  • Ages: 18-65
  • Compensation: Provided
  • Time Required: Up to 3 visits or approximately 3 hours

Treating Insomnia & OSA with Cognitive Behavioral Therapy

Does your mind race at night when you're trying to sleep? Our researchers are studying how people with insomnia and obstructive sleep apnea can benefit from cognitive behavioral therapy, a goal-oriented type of treatment that aims to identify and change inaccurate or negative thinking patterns...

  • Gender: Any Gender
  • Ages: 21-80
  • Compensation: Provided
  • Time Required: Not Specified

Identifying Characteristics and Patterns of Asthma

Our researchers are working to identify the clinical, physiologic, genetic and molecular characteristics of asthmatics.

  • Gender: Any Gender
  • Ages: 5+
  • Compensation: Provided
  • Time Required: 2-4 office visits and up to 3 follow up phone calls

Impact of triple Combination Therapy for People with CF with Sinusitis

In addition to its impact on lung function and sweat chloride, a new medication regimen may improve chronic sinusitis signs and symptoms and sense of smell for people with CF.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 6 months

New Trial Medication for Pulmonary Arterial Hypertension

By adding a new investigational Pulmonary Arterial Hypertension (PAH) medication to your current therapy, you could experience relaxed and widened artery walls.

  • Gender: Any Gender
  • Ages: 18-75
  • Compensation: Provided
  • Time Required: Up to 42 months

Investigational PAH Medication CXA-10

A new investigational medication for Pulmonary Arterial Hypertension is thought to treat inflammation and lower the pressure in blood vessels from the heart to lungs.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: Up to 134 days

The Immunoregulatory Role of Alveolar Macrophages in Chronic Beryllium Disease

By participating in our study, you can help forward research on lung disease. Our researchers are hoping to learn more about the blood cells involved in the development of scarring lung diseases and create new treatment therapies.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 5 hours over 2 visits

New Medication for Early-Stage Non-small cell Lung Cancer

Already approved for advanced non-small cell lung cancer, atezolizumab is a drug that may help those with early-stage lung cancer, as well. Participants in this clinical trial may take atezolizumab in conjunction with their chemotherapy treatments.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Not Provided
  • Time Required: The screening period may last up to 6 weeks and involve up to 2 visits to the clinic.

Hypersensitivity Pneumonitis and the Immune System

Help us look at how specific white blood cells are associated with hypersensitivity pneumonitis (HP) and impact how your disease affects you.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: Approximately 9 hours over 3 study visits

New Investigational Drug for CF Patients with NTM Infection

A new study is looking at an investigational drug that stimulates immune response to fight infection. If you have cystic fibrosis and an ongoing mycobacterial infection, this trial may be right for you.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: Study involvement will last for about 18 months.

New Medication for Osteoarthritis Knee Pain

Do you have mild to moderate osteoarthritis in your knee? Our researchers are conducting a study on an FDA-approved drug that may reduce osteoarthritis knee pain and improve function.

  • Gender: Any Gender
  • Ages: 21-80
  • Compensation: Provided
  • Time Required: 5 visits over 12 months

Lung Injury from Military Deployment

The purpose of this study is to learn more about lung disease found in contractors and U.S. military personnel serving in Iraq and Afghanistan after September 11, 2001.

  • Gender: Any Gender
  • Ages: 18-70
  • Compensation: Provided
  • Time Required: 1 to 2 visits

Pulmonary Sarcoidosis Investigational Medication

This research study evaluates an investigational medication called Acthar® Gel (Acthar) as a potential treatment of pulmonary sarcoidosis.

  • Gender: Any Gender
  • Ages: 18-90
  • Compensation: Provided
  • Time Required: Participants in the study inject the medication twice a week at home and have appointments every 4 weeks.

Sexual and Reproductive Health Survey of Women with Cystic Fibrosis

The purpose of this research study is to identify the general and disease-specific sexual and reproductive health concerns of women with Cystic Fibrosis (CF).

  • Gender: Any Gender
  • Ages: 25+
  • Compensation: Provided
  • Time Required: 25-40 minutes to complete one online survey

Link Between Rheumatoid Arthritis & Lung Disease

Our researchers are trying to understand the connection, as well as how to prevent and treat lung disease in RA patients.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Not Provided
  • Time Required: 6 in-person visits, performed every year over 4 years

ILD & Early Rheumatoid Arthritis

Our researchers are trying to understand how interstitial lung disease (ILD) develops in people with rheumatoid arthritis (RA), and how it may impact their quality of life.

  • Gender: Any Gender
  • Ages: 18-90
  • Compensation: Not Provided
  • Time Required: 5 in-person visits over 18 months

PAH & Scleroderma Medication Study

New drug, Tecfidera, may help with pulmonary arterial hypertension (PAH) by reducing inflammation.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 6 visits over 40 weeks

Idiopathic Pulmonary Fibrosis (IPF)

The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).

  • Gender: Any Gender
  • Ages: 40-95
  • Compensation: Provided
  • Time Required: 5 visits over a 6-month period, visits are every 3 months

Current & Former Smokers Needed for Lung Research Study

Our researchers are studying the lungs of current and former smokers to understand how to improve the diagnosis and treatment of Chronic Obstructive Pulmonary Disease (COPD), a disease that is common among smokers. You do not need to have COPD to participate in this study.

  • Gender: Any Gender
  • Ages: 55-77
  • Compensation: Provided
  • Time Required: 1-2 hour visit (can be scheduled immediately after your CT if there is space available)

Immune Pathways & Development of Sarcoidosis

If you are an adult with sarcoidosis who is not on immunosuppressive therapy, you may be able to help our researchers learn more about different types of sarcoidosis and how it develops.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: Up to 2 visits

Mineral Dust & Lung Disease

Our researchers are studying lung diseases that develop from inhaling mineral dust over time. Although the cause of diseases such as "black lung" are known, it is not well understood why some people develop these diseases and others don't.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Not Provided
  • Time Required: Not Specified

Impact of Combination Therapy on Cystic Fibrosis (TEACH Study)

The purpose of this study is to determine how two medications, azithromycin and inhaled tobramycin, work when taken together to treat cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) lung infections.

  • Gender: Any Gender
  • Ages: 12+
  • Compensation: Provided
  • Time Required: 3 visits over 6 weeks totaling up to 7 hours

New Medication for Uncontrolled Eczema

Are you one of the many people with atopic dermatitis (eczema) who continues to have dry, itchy skin, and repeat infections that are not controlled by your medicine? Our researchers are seeking participants for a clinical trial that will test a medication called dupilumab that was recently...

  • Gender: Any Gender
  • Ages: 18-75
  • Compensation: Provided
  • Time Required: 10 visits and 1 telephone call over about 6-7 months

New Antibody Targets Severe Asthma

Is your asthma poorly controlled despite using inhalers? Our researchers are studying an investigational medicine that targets a substance known to play a role in causing asthma. You may be able to help them determine if this medication is effective in treating severe asthma.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 19 visits over 69-71 weeks

Investigational Drug Targets Cystic Fibrosis Mutation and Regulator

Our researchers are studying glycerol phenylbutyrate (GPBA), also known as RAVICTI®, to determine how safe it is and how well people tolerate it in the treatment of cystic fibrosis (CF).

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 5 visits totalling up to 21 hours

Rheumatoid Arthritis & Interstitial Lung Disease Medication

Do you have rheumatoid arthritis and interstitial lung disease (RA-ILD)? You may be able to help our researchers determine if people with RA-ILD can benefit from a medication called Pirfenidone, which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic...

  • Gender: Any Gender
  • Ages: 18-85
  • Compensation: Provided
  • Time Required: 10 visits & 1 phone call (22 hours over 56 weeks)

Healthy Participants Needed for Lung Disease Study

Are you 18 or older with no history of chronic lung conditions? You may be able to help our researchers better understand lung disease. Compensation provided.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 60-90 minute session

OPUS Registry for Patients Using Opsumit®

The purpose of this study is to learn more about how Opsumit® (the commercial form of the medication macitentan) is used in clinical practice to treat pulmonary arterial hypertension (PAH) and other conditions.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 1 year

Investigational Medication for COPD Lung Damage

Adults age 40 or older are needed to help our researchers determine if an investigational medication can help slow damage to the lungs in people who have COPD with emphysema.

  • Gender: Any Gender
  • Ages: 40+
  • Compensation: Provided
  • Time Required: 7 visits, approximately 19 hours

Investigational Medication Sirolimus for Lymphangioleiomyomatosis (LAM)

The purpose of this study is to see if a drug called sirolimus slows development of lymphangioleiomyomatosis (LAM), a lung disease in which abnormal cells growing inside the lungs prevent them from working properly.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 2 years

Early-Stage Lung Cancer Surgery vs. Radiation Therapy Comparison

The purpose of this study is to gather information about treatment of early-stage lung cancer in order to compare the effectiveness of surgery versus radiation therapy, potentially improving outcomes for patients with early-stage lung cancer.

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Provided
  • Time Required: 4 hours, 45 mins.

Can Investigational Drug Benefit Lung Cancer Surgery Patients?

The purpose of this clinical trial is to see if it better to receive an investigational medication or no further treatment after surgery (and possibly chemotherapy) to remove non-small cell lung cancer (NSCLC).

  • Gender: Any Gender
  • Ages: 18+
  • Compensation: Not Provided
  • Time Required: Up to 12 months

Can Investigational Medication Benefit FHP Patients?

The purpose of this clinical trial is to study the safety and potential benefits of treating fibrotic hypersensitivity pneumonitis (FHP) with an investigational medication.

  • Gender: Any Gender
  • Ages: 18-80
  • Compensation: Provided
  • Time Required: 8 visits and 6 phone calls totaling about 12 hours of participation over 13 months

Atopic Dermatitis (Eczema) & Skin-Infection Risk

If you or your child age 3 or older has atopic dermatitis (eczema), you may be able to help our researchers learn why some people with eczema have increased risk of skin infection.

  • Gender: Any Gender
  • Ages: 3-80
  • Compensation: Provided
  • Time Required: 1 or more visits

Pulmonary Fibrosis & Genetic Factors

The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.

  • Gender: Any Gender
  • Ages: Not Specified
  • Compensation: Not Provided
  • Time Required: Not Specified

The PROMISE Study: An Observational Study of Triple Combination Therapy for Cystic Fibrosis

This is an observational study to evaluate the biological and clinical effects of triple-combination therapy (TCT), elexacaftor/tezacaftor/ivacaftor, in people with cystic fibrosis (CF) before and after starting this therapy, as prescribed by their doctor.

  • Gender: Any Gender
  • Ages: 12+
  • Compensation: Provided
  • Time Required: 6 visits over 25 months

MANDALA Asthma Study

New study drug combines two medications known for asthma relief may help manage the symptoms of moderate to severe asthma in both children and adults.

  • Gender: Any Gender
  • Ages: 4+
  • Compensation: Provided
  • Time Required: After screening, treatment will last from 24 to 36 weeks

Identifying Characteristics and Patterns of Asthma

Our researchers are working to identify the clinical, physiologic, genetic and molecular characteristics of asthmatics.

  • Gender: Any Gender
  • Ages: 5+
  • Compensation: Provided
  • Time Required: 2-4 office visits and up to 3 follow up phone calls

Eczema & Inflammation

National Jewish Health researchers are studying a new phosphate cream that could reduce painful inflammation. Children ages 2 to 17 with atopic dermatitis may qualify. Learn more.

  • Gender: Any Gender
  • Ages: 2-17
  • Compensation: Provided
  • Time Required: 5 visits over 12 weeks

Impact of Combination Therapy on Cystic Fibrosis (TEACH Study)

The purpose of this study is to determine how two medications, azithromycin and inhaled tobramycin, work when taken together to treat cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) lung infections.

  • Gender: Any Gender
  • Ages: 12+
  • Compensation: Provided
  • Time Required: 3 visits over 6 weeks totaling up to 7 hours

Combination Therapy for Pediatric Asthma Patients

Our researchers are studying an investigational combination of medications, one used to treat asthma in adults and the other not yet approved to treat adult asthma, to determine if it can improve symptoms and lung function in asthma patients age 5 to 17.

  • Gender: Any Gender
  • Ages: 5-17
  • Compensation: Provided
  • Time Required: 7 visits up to 29 weeks

Teens Age 12-17 with Asthma

Our researchers are studying an investigational medication to determine if it improves lung function in teens with asthma. By blocking a key receptor that causes inflammation in the lungs, the medication may improve and prevent symptoms such as wheezing and shortness of breath.

  • Gender: Any Gender
  • Ages: 12-17
  • Compensation: Provided
  • Time Required: About 9 visits over approximately 19 weeks

Link Between Eczema & Food Allergies in Newborns

Are you pregnant? Do you have a family history of allergic disease (asthma, eczema, environmental allergies, hay fever, etc.)? You may be able to help our researchers determine if your child and others are at risk of developing eczema and food allergies.

  • Gender: Any Gender
  • Ages: Parents 18-50, newborns 3-6 months
  • Compensation: Not Provided
  • Time Required: Four 1-hour visits over 6 months

Atopic Dermatitis (Eczema) & Skin-Infection Risk

If you or your child age 3 or older has atopic dermatitis (eczema), you may be able to help our researchers learn why some people with eczema have increased risk of skin infection.

  • Gender: Any Gender
  • Ages: 3-80
  • Compensation: Provided
  • Time Required: 1 or more visits